COMPANY RESEARCHAUBE00 is an oral macrocyclic peptide in Phase 1. LUNA18 was discontinued in 2025; the company report confirms oral absorption in humans.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
AUBE00 is an oral pan-KRAS macrocyclic peptide from the SnipeTide platform; Phase 1 began in 2025.
LUNA18 was discontinued in 2025. The annual report states that human oral absorption was confirmed and development shifted to AUBE00. This is company-reported information, not publicly available quantitative clinical data.
As of 2026-09-30, the website also listed AQUA07, an oral macrocyclic allosteric ALK inhibitor. Its clinical stage was not confirmed in this review.
The July 24 company release confirms clinical entry; the Japanese registry identifies an oral Phase 1 study recruiting participants.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| AUBE00 | pan-KRAS（GDP） · Solid tumors | Phase 1 | No results found in this review |
| LUNA18 / paluratide | pan-RAS · Solid tumors | 已终止 | Human absorption reported by the company; quantitative data not disclosed |
| AQUA07 | Allosteric ALK · ALK-positive non-small cell lung cancer | Phase 1 | No results found in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.